These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34897154)

  • 21. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
    Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
    Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
    J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
    Hara T; Ohara T; Taniguchi M; Sakai H; Oka K; Iwai N; Tsuji T; Okuda T; Nagata A; Komaki T; Sakagami J; Kagawa K
    Intern Med; 2021 Aug; 60(15):2437-2443. PubMed ID: 33612683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
    Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
    Adv Ther; 2020 Sep; 37(9):4033-4042. PubMed ID: 32754824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
    Cotter TG; Jensen DM
    Drug Des Devel Ther; 2019; 13():2565-2577. PubMed ID: 31534310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
    Foster GR; Asselah T; Kopecky-Bromberg S; Lei Y; Asatryan A; Trinh R; Zadeikis N; Mensa FJ
    PLoS One; 2019; 14(1):e0208506. PubMed ID: 30601818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
    Wang CY; Liu J; Wen J; Ma HX; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2021 Dec; 29(12):1194-1195. PubMed ID: 35045636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature.
    Yamazaki T; Joshita S; Ichijo T; Kobayashi H; Wakabayashi SI; Yamashita Y; Sugiura A; Kawakami F; Nakazawa H; Umemura T
    J Infect Chemother; 2021 Dec; 27(12):1750-1755. PubMed ID: 34344581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir.
    Quintero García D; Sebastián Cuevas FJ; Crehuá Gaudiza E
    Rev Esp Enferm Dig; 2021 Feb; 113(2):150-151. PubMed ID: 33207896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.
    Abutaleb A; Kottilil S; Wilson E
    Hepatol Int; 2018 May; 12(3):214-222. PubMed ID: 29845496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia.
    Chen HW; Hsieh CB; Hsieh TY; Lin JC
    J Formos Med Assoc; 2021 Jun; 120(6):1408-1409. PubMed ID: 33272749
    [No Abstract]   [Full Text] [Related]  

  • 32. Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir.
    Totsuka M; Honda M; Kanda T; Ishii T; Matsumoto N; Yamana Y; Kaneko T; Mizutani T; Takahashi H; Kumagawa M; Sasaki R; Masuzaki R; Kanezawa S; Nirei K; Yamagami H; Matsuoka S; Ohnishi H; Okamoto H; Moriyama M
    Intern Med; 2021 Jul; 60(13):2061-2066. PubMed ID: 33518580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
    Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
    J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
    Poordad F; Felizarta F; Yao BB; Overcash JS; Hassanein T; Agarwal K; Gane E; Shaw D; Waters M; Krishnan P; Topp A; Burroughs M; Nevens F
    Liver Int; 2022 Jun; 42(6):1278-1286. PubMed ID: 35220658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Jensen SB; Fahnøe U; Pham LV; Serre SBN; Tang Q; Ghanem L; Pedersen MS; Ramirez S; Humes D; Pihl AF; Filskov J; Sølund CS; Dietz J; Fourati S; Pawlotsky JM; Sarrazin C; Weis N; Schønning K; Krarup H; Bukh J; Gottwein JM
    Hepatology; 2019 Sep; 70(3):771-787. PubMed ID: 30964552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review.
    Volpicelli L; Biliotti E; Milito C; Cruciata A; Spaziante M; Rivano Capparuccia M; Taliani G; Mezzaroma I
    Infez Med; 2020 Dec; 28(4):616-620. PubMed ID: 33257639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
    Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
    J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
    Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K;
    Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
    Dietz J; Sarrazin C
    J Hepatol; 2021 Jul; 75(1):254-255. PubMed ID: 33892009
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.